In vivo endorectal dosimetry of prostate tomotherapy using dual MOSkin detectors.

Verification of dose to the anterior rectal wall in helical tomotherapy to the prostate is important due to the close proximity of the rectal wall to the treatment field. The steep dose gradient makes these measurements challenging. A phantom-based study was completed, aimed at developing a system for measurement of anterior rectal wall doses during hypofractionated prostate stereotactic body radiotherapy (SBRT) utilizing tomotherapy delivery. An array of four dual MOSkinTM dosimeters, spaced 1 cm apart, was placed on a replica Rectafix® immobilization spacer device. This Perspex probe is a more rigid alternative to rectal balloons, to improve geometric reproducibility. The doses at each point were measured in real time and compared to doses calculated by the treatment planning system (TPS). Additionally, distance-to-agreement (DTA) measurements were acquired to assist in the comparison of measured and predicted doses. All dual MOSkin detectors measured dose to within ± 5% of the TPS at the anterior rectal wall. Whilst several points were outside of experimental error, the largest deviation from the TPS predicted dose represented a DTA of only 1.3 mm, within the acceptable DTA tolerance of 3 mm. Larger deviations of up to -11.9% were observed for the posterior and side walls; however, if acceptable DTA measurements are accounted for, then an agreement of 75% was observed. Although larger differences were observed at the other rectal wall locations, the overall effect of dose at these points was not as significant, given the lower doses. Despite the very high-dose gradient region, real-time measurements of the anterior rectal wall doses were within acceptable limits of TPS-predicted doses. The differences between measured and planned data were due to difficulties in precisely locating each detector on the TPS dose grid, which presented large variations in dose between CT voxels in regions of steep dose gradients. The dual MOSkin system would, therefore, be a useful device for detecting errors in real time, such as patient shifts or incorrect setup, during tomotherapy of the prostate.

Characterization of MOSkin detector for in vivo skin dose measurement during megavoltage radiotherapy.

In vivo dosimetry is important during radiotherapy to ensure the accuracy of the dose delivered to the treatment volume. A dosimeter should be characterized based on its application before it is used for in vivo dosimetry. In this study, we characterize a new MOSFET-based detector, the MOSkin detector, on surface for in vivo skin dosimetry. The advantages of the MOSkin detector are its water equivalent depth of measurement of 0.07 mm, small physical size with submicron dosimetric volume, and the ability to provide real-time readout. A MOSkin detector was calibrated and the reproducibility, linearity, and response over a large dose range to different threshold voltages were determined. Surface dose on solid water phantom was measured using MOSkin detector and compared with Markus ionization chamber and GAFCHROMIC EBT2 film measurements. Dependence in the response of the MOSkin detector on the surface of solid water phantom was also tested for different (i) source to surface distances (SSDs); (ii) field sizes; (iii) surface dose; (iv) radiation incident angles; and (v) wedges. The MOSkin detector showed excellent reproducibility and linearity for dose range of 50 cGy to 300 cGy. The MOSkin detector showed reliable response to different SSDs, field sizes, surface, radiation incident angles, and wedges. The MOSkin detector is suitable for in vivo skin dosimetry.

eXaSkin: A novel high-density bolus for 6MV X-rays radiotherapy.

PURPOSE: To evaluate eXaSkin, a novel high-density bolus alternative to commercial tissue-equivalent Superflab, for 6MV photon-beam radiotherapy. MATERIALS AND METHODS: We delivered a 10 × 10 cm2 open field at 90° and head-and-neck clinical plan, generated with the volumetric modulated arc therapy (VMAT) technique, to an anthropomorphic phantom in three scenarios: with no bolus on the phantom's surface, with Superflab, and with eXaSkin. In each scenario, we measured dose to a central planning target volume (PTV) in the nasopharynx region with an ionization chamber, and we measured dose to the skin, at three different positions within the vicinity of a neck lymph node PTV, with MOSkin™, a semiconductor dosimeter. Measurements were compared against calculations with the treatment planning system (TPS). RESULTS: For the static field, MOSkin results underneath the eXaSkin were in agreement with calculations to within 1.22%; for VMAT, to within 5.68%. Underneath Superflab, those values were 3.36% and 11.66%. The inferior agreement can be explained by suboptimal adherence of Superflab to the phantom's surface as well as difficulties in accurately reproducing its placement between imaging and treatment session. In all scenarios, dose measured at the central target agreed to within 1% with calculations. CONCLUSIONS: eXaSkin was shown to have superior adaptation to the phantom's surface, producing minimal air gaps between the skin surface and bolus, allowing for accurate positioning and reproducibility of set-up conditions. eXaSkin with its high density material provides sufficient build-up to achieve full skin dose with less material thickness than Superflab.

Characterisation of out-of-field dose at shallow depths for external beam radiotherapy: implications for eye lens dose.

Re-evaluation of the eye lens radio-sensitivity by the ICRP in 2011 resulted in a significant reduction of the threshold for lens opacities from 8 Gy to 0.5 Gy. This has led to an increase in concern for eye lens doses from treatment sites further from the eye than previously considered. The aim of this study was to examine the out-of-field dose far from the field edge and develop an effective method to accurately characterise the constituent components of this dose at varying depths. Dose profile scans using a 0.6 cm3 cylindrical ionisation chamber in a motorised water tank were compared with previous studies and displayed good agreement. At points more than 20 cm from the field edge patient scatter becomes insignificant, and the dose is dominated by head leakage and collimator scatter. Point depth-dose measurements made with a Roos parallel plate chamber in solid water at distances of 52 cm and 76 cm from central axis showed that the highest dose is at the surface. Since the sensitive region of the eye can be as shallow as 3 mm, in vivo measurements carried out with a detector with buildup more than 3 mm water equivalent thickness may be underestimating the dose to the lens. It is therefore recommended that for in vivo measurements for the eye lens further than 20 cm from the field edge the detector should have only 3 mm build-up material over the effective point of measurement.

Dosimetric effects of brass mesh bolus on skin dose and dose at depth for postmastectomy chest wall irradiation.

PURPOSE: To investigate the feasibility of using the brass mesh bolus as an alternative to tissue- equivalent bolus for post mastectomy chest wall cancer by characterizing the dosimetric effects of the 2-mm fine brass bolus on both the skin dose, the dose at depth and spatial distribution. MATERIALS AND METHODS: Surface dose and percent depth dose data were acquired for a 6 MV photon beam in a solid water phantom using MOSkin™, Gafchromic EBT3 film and an Advanced Markus ionization chamber. Data were acquired for the case of: no bolus, Face-up bass bolus, Face-down brass bolus, double brass bolus, 0.5 cm and 1.0 cm of Superflab TE bolus. The exit doses were also measured via MOSkin™ dosimeter and Markus ionization chamber. Gafchromic EBT3 film strips were used to plot dose profile at surface and 10 cm depth for Face-up brass, Face-down brass, double brass, 0.5 cm and 1.0 cm of Superflab TE bolus. RESULTS: The surface dose measured via MOSkin™ dosimeter increased from 19.2 ±â€¯1.0% to 63.1 ±â€¯2.1% under Face-up brass discs, 51.2 ±â€¯1.2% under Face-up brass spaces, 61.5 ±â€¯0.5% under Face-down brass discs, and 41.3 ±â€¯2.1% under Face-down brass spaces. The percentage difference in the dose measured under brass discs between Face-up versus Face-down was less than 2% for entrance dose and 10% for exit dose, whereas the percentage difference under brass spaces was approximately 3% for entrance dose and about 5% for the exit dose. Gafchromic EBT3 film strip measurements show that the mesh bolus produced ripple beam profiles due to the mesh brass construction. CONCLUSIONS: Brass bolus does not significantly change dose at depth (less than 0.5%), and the surface dose is increased similar to TE bolus. Considering this, brass mesh may be used as a substitute for TE bolus to increase superficial dose for chest wall tangent plans.

In vivo real-time rectal wall dosimetry for prostate radiotherapy.

Rectal balloons are used in external beam prostate radiotherapy to provide reproducible anatomy and rectal dose reductions. This is an investigation into the combination of a MOSFET radiation detector with a rectal balloon for realtime in vivo rectal wall dosimetry. The MOSFET used in the study is a radiation detector that provides a water equivalent depth of measurement of 70 microm. Two MOSFETs were combined in a face-to-face orientation. The reproducibility, sensitivity and angular dependence were measured for the dual MOSFET in a 6 MV photon beam. The dual MOSFET was combined with a rectal balloon and irradiated with hypothetical prostate treatments in a phantom. The anterior rectal wall dose was measured in real time and compared with the planning system calculated dose. The dual MOSFET showed angular dependence within +/-2.5% in the azimuth and +2.5%/-4% in the polar axes. When compared with an ion chamber measurement in a phantom, the dual MOSFET agreed within 2.5% for a range of radiation path lengths and incident angles. The dual MOSFET had reproducible sensitivity for fraction sizes of 2-10 Gy. For the hypothetical prostate treatments the measured anterior rectal wall dose was 2.6 and 3.2% lower than the calculated dose for 3DCRT and IMRT plans. This was expected due to limitations of the dose calculation method used at the balloon cavity interface. A dual MOSFET combined with a commercial rectal balloon was shown to provide reproducible measurements of the anterior rectal wall dose in real time. The measured anterior rectal wall dose agreed with the expected dose from the treatment plan for 3DCRT and IMRT plans. The dual MOSFET could be read out in real time during the irradiation, providing the capability for real-time dose monitoring of the rectal wall dose during treatment.